Eisai Co., Ltd. (ESALF)

40,01 0,00 (0,00%) Al cierre: 01:54PM EDT

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 11.076

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Haruo Naito	CEO, Representative Corporate Officer & Director	N/A	N/A	1947
Mr. Gary Hendler	Senior VP & President of EMEA Region	N/A	N/A	1966
Dr. Lynn D. Kramer FAAN, M.D.	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	N/A	N/A	1950
Ms. Yanhui Feng	Senior Vice President	N/A	N/A	1972
Dr. Nadeem Sarwar Ph.D.	President	N/A	N/A	N/A
Mitsuru Shomon	VP & CFO	N/A	N/A	N/A
Mr. Yasushi Okada	Representative Corporate Officer, COO, Industry Affairs, China Business & Data Integrity	N/A	N/A	1958
Makoto Hoketsu	VP & Chief Information Officer	N/A	N/A	N/A
Mr. Masatomi Akana	Chief Gov. Rel. and IR Officer, SVP of Global Value, Acc., Japan Subs, General, Env. & Safety Aff.	N/A	N/A	1967
Mr. Kenta Takahashi	Executive VP of IP, Internal Audit & Control, General Counsel and Chief Compliance Officer	N/A	N/A	1959

Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Eisai Co., Ltd., a día 1 de abril de 2024, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 1; Derechos de los accionistas: 6; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.